Clinical effect of direct-acting antiviral agents in treatment of chronic hepatitis C patients with thrombocytopenia
10.3969/j.issn.1001-5256.2022.01.014
- VernacularTitle:直接抗病毒药物治疗慢性丙型肝炎合并血小板减少患者的效果分析
- Author:
Tao WANG
1
,
2
,
3
;
Fenghui LI
1
,
2
,
3
;
Jing LIANG
1
,
2
,
3
;
Huiling XIANG
1
,
2
,
3
;
Fang LIU
1
,
2
,
3
;
Hongmin LYU
1
,
2
,
3
;
Baoxin QIAN
1
,
2
,
3
;
Jiajun TIAN
1
,
2
,
3
Author Information
1. Department of Gastroenterology and Hepatology, Tianjin Third Central Hospital
2. Tianjin Key Laboratory of Extracorporeal Life Support for Critical Diseases
3. Artificial Cell Engineering Technology Research Center, Tianjin 300170, China
- Publication Type:Original Articles_Viral Hepatitis
- Keywords:
Hepatitis C, Chronic;
Antiviral Agents;
Thrombocytopenia;
Therapeutics
- From:
Journal of Clinical Hepatology
2022;38(1):91-96
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the clinical effect of direct-acting antiviral agent (DAA) in the treatment of chronic hepatitis C (CHC) patients with thrombocytopenia and its effect on platelet count (PLT). Methods A retrospective analysis was performed for 83 CHC patients with thrombocytopenia (PLT < 150×10 9 /L) who received the DAA treatment regimen without interferon for 12-24 weeks in Tianjin Third Central Hospital from April 2018 to March 2019, and the changes in virologic response, liver function parameters, PLT, and liver stiffness measurement (LSM) were evaluated at the end of treatment (EOT) and at week 12 after EOT. Quantitative data accord with normal distribution were compared by repeated measures ANOVA. Normal transformation was performed before the comparison between skewed data, then repeated measures ANOVA was carried out. A logistic regression analysis was used to investigate the predictive factors for PLT elevation, and the receiver operating characteristic (ROC) curve was plotted to analyze the value of LSM in predicting PLT elevation after treatment. Results Among the 83 CHC patients with thrombocytopenia, 61.4% had liver cirrhosis, and the rate of sustained virologic response at week 12 after the end of treatment (SVR12) was 98.8%. From baseline to EOT and SVR12, the patients had significant reductions in the serum levels of aspartate aminotransferase, alanine aminotransferase, gamma-glutamyl transpeptidase, total bilirubin, and globin, a significant increase in the serum level of albumin, and a significant reduction in LSM (all P < 0.05). For all patients, PLT at EOT and SVR12 was significantly higher than that at baseline [EOT vs baseline: (110.4±44.6)×10 9 /L vs (97.8±33.2)×10 9 /L, P < 0.01; SVR12 vs baseline: (109.0±47.7)×10 9 /L vs (97.8±33.2)×10 9 /L, P < 0.01]. At SVR12, there were significant differences in the proportion of patients with liver cirrhosis, baseline LSM, and baseline white blood cell count between the PLT elevation group and the non-PLT elevation group (all P < 0.05). The multivariate logistic regression analysis showed that LSM was an independent predictive factor for significant PLT elevation after DAA treatment (odds ratio=0.929, 95% confidence interval: 0.864-0.999, P < 0.05). Baseline LSM had an area under the ROC curve of 0.644 in predicting PLT elevation, with a sensitivity of 81.0% and a specificity of 48.6% at a cut-off value of 20.15 kPa. The patients with PLT > 100×10 9 /L at baseline had a greater increase in PLT( P < 0.05). Conclusion CHC patients with thrombocytopenia have significant improvements in liver function and LSM after receiving DAA treatment and obtaining SVR12, and baseline LSM is an independent predictive factor for PLT elevation. There is a significant increase in PLT from baseline to EOT and SVR12.
